<DOC>
	<DOCNO>NCT01953783</DOCNO>
	<brief_summary>This phase 1 , 2-part , open-label study 4 6 pharmacokinetic-evaluable patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>Mass Balance , Pharmacokinetics Metabolism Study IXAZOMIB</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old Histologic cytologic diagnosis advance metastatic solid tumor lymphoma standard , curative , lifeprolonging therapy exist effective Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Female patient postmenopausal least 1 year OR surgically sterile OR childbearing potential , agree practice 2 effective method contraception time entire study 90 day last dose study drug OR agree practice true abstinence Male patient agree practice effective barrier contraception entire study 90 day last dose study drug OR agree practice true abstinence Voluntary write consent Suitable venous access conduct blood sampling Recovered reversible effect prior anticancer therapy Patients meeting follow exclusion criterion enrol study : Female patient lactate breastfeed positive serum pregnancy test Serious medical psychiatric illness could interfere study Treatment investigational product radiotherapy within 21 day first dose study drug Peripheral neuropathy &gt; Grade 2 Systemic treatment strong moderate inhibitor CYP1A2 , strong moderate inhibitor CYP3A , clinically significant CYP3A inducer use Ginkgo biloba St. John 's wort within 14 day first dose study drug Symptomatic brain metastasis . Patients brain metastasis : must stable neurologic status follow local therapy ( surgery radiation ) least 2 week completion definitive therapy ; must without neurologic dysfunction would confound evaluation neurologic AEs Ongoing treatment corticosteroid Major surgery within 14 day precede first dose study drug Infection require systemic intravenous antibiotic therapy serious infection within 14 day first dose study drug Lifethreatening illness unrelated cancer Known hepatitis B surface antigen positive , know suspect active hepatitis C infection human immunodeficiency virus ( HIV ) positive Diagnosed treat another malignancy within 2 year first dose , OR previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection Any cardiovascular condition specify study protocol Known GI disease GI procedure could interfere oral absorption tolerance IXAZOMIB History urinary and/or fecal incontinence Inability comply study procedure visit schedule include requirement inpatient confinement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>